{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:36:05Z","timestamp":1791423365249,"version":"4.3.3"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Antimicrobial therapy is essential for the treatment of enteric fever, the infection caused by Salmonella serovars Typhi and Paratyphi A. However, an increase in resistance to key antimicrobials and the emergence of MDR and XDR in Salmonella Typhi poses a major threat for efficacious outpatient treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We recently identified tebipenem, an oral carbapenem licensed for use for respiratory tract infections in Japan, as a potential alternative treatment for MDR\/XDR Shigella spp. Here, we aimed to test the in vitro antibacterial efficacy of this drug against MDR and XDR typhoidal Salmonella.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We determined the in vitro activity of tebipenem in time\u2013kill assays against a collection of non-XDR and XDR Salmonella Typhi and Salmonella Paratyphi A (non-XDR) isolated in Nepal and Bangladesh. We also tested the efficacy of tebipenem in combination with other antimicrobials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found that both XDR and non-XDR Salmonella Typhi and Salmonella Paratyphi A are susceptible to tebipenem, exhibiting low MICs, and were killed within 8\u201324\u2009h at 2\u20134\u00d7MIC. Additionally, tebipenem demonstrated synergy with two other antimicrobials and could efficiently induce bacterial killing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Salmonella Paratyphi A and XDR Salmonella Typhi display in vitro susceptibility to the oral carbapenem tebipenem, while synergistic activity with other antimicrobials may limit the emergence of resistance. The broad-spectrum activity of this drug against MDR\/XDR organisms renders tebipenem a good candidate for clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkab326","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T11:13:59Z","timestamp":1629285239000},"page":"3197-3200","source":"Crossref","is-referenced-by-count":14,"title":["Tebipenem as an oral alternative for the treatment of typhoid caused by XDR<i>Salmonella<\/i>Typhi"],"prefix":"10.1093","volume":"76","author":[{"given":"Elli","family":"Mylona","sequence":"first","affiliation":[{"name":"University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK"},{"name":"Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phat","family":"Voong Vinh","sequence":"additional","affiliation":[{"name":"The Hospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Aga Khan University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhilasha","family":"Karkey","sequence":"additional","affiliation":[{"name":"Nepal Academy of Health Sciences, Oxford University Clinical Research Unit, Kathmandu, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Dongol","sequence":"additional","affiliation":[{"name":"Nepal Academy of Health Sciences, Oxford University Clinical Research Unit, Kathmandu, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyen","family":"Ha Thanh","sequence":"additional","affiliation":[{"name":"The Hospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judd","family":"Walson","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Disease, Center for Emerging and Re-emerging Infectious Diseases, University of Washington School of Medicine, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluis","family":"Ballell","sequence":"additional","affiliation":[{"name":"GSK Global Health, Tres Cantos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fern\u00e1ndez \u00c1lvaro","sequence":"additional","affiliation":[{"name":"GSK Global Health, Tres Cantos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Qamar","sequence":"additional","affiliation":[{"name":"Aga Khan University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Baker","sequence":"additional","affiliation":[{"name":"University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK"},{"name":"Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"2021111722581030300_dkab326-B1","doi-asserted-by":"crossref","first-page":"1799654","DOI":"10.1080\/19490976.2020.1799654","article-title":"Antimicrobial resistance in enteric bacteria: current state and next-generation solutions","volume":"12","author":"Wallace","year":"2020","journal-title":"Gut Microbes"},{"key":"2021111722581030300_dkab326-B2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1473-3099(18)30685-6","article-title":"The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017","volume":"19","author":"Stanaway","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021111722581030300_dkab326-B3","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ng.3281","article-title":"Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events","volume":"47","author":"Wong","year":"2015","journal-title":"Nat Genet"},{"key":"2021111722581030300_dkab326-B4","doi-asserted-by":"crossref","first-page":"e00105-18","DOI":"10.1128\/mBio.00105-18","article-title":"Emergence of an extensively drug-resistant Salmonella enterica serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third- generation cephalosporins","volume":"9","author":"Klemm","year":"2018","journal-title":"mBio"},{"key":"2021111722581030300_dkab326-B5","doi-asserted-by":"crossref","first-page":"618","DOI":"10.15585\/mmwr.mm6920a2","article-title":"Update on extensively drug-resistant Salmonella serotype Typhi infections among travelers to or from Pakistan and report of ceftriaxone-resistant Salmonella serotype Typhi infections among travelers to Iraq \u2014 United States, 2018\u20132019","volume":"69","author":"Fran\u00e7ois Watkins","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021111722581030300_dkab326-B6","year":"2021"},{"key":"2021111722581030300_dkab326-B7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/0009922819881203","article-title":"Drug-resistant Salmonella typhi in Pakistan","volume":"59","author":"Petrin","year":"2020","journal-title":"Clin Pediatr (Phila)"},{"key":"2021111722581030300_dkab326-B8","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1093\/cid\/ciaa1773","article-title":"Spontaneous emergence of azithromycin resistance in independent lineages of Salmonella Typhi in Northern India","volume":"72","author":"Carey","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2021111722581030300_dkab326-B9","article-title":"Repurposing tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively-drug resistant (XDR) Shigella spp","author":"Alvaro","year":"2021","journal-title":"Res Square"},{"key":"2021111722581030300_dkab326-B10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/14787210.2018.1496821","article-title":"Tebipenem, the first oral carbapenem antibiotic","volume":"16","author":"Jain","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2021111722581030300_dkab326-B11","doi-asserted-by":"crossref","first-page":"e02618-18","DOI":"10.1128\/AAC.02618-18","article-title":"Antimicrobial activity evaluation of tebipenem (SPR859), an orally available carbapenem, against a global set of Enterobacteriaceae isolates, including a challenge set of organisms","volume":"63","author":"Ryan Arends","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021111722581030300_dkab326-B12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)00530-7","article-title":"Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial","volume":"16","author":"Arjyal","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2021111722581030300_dkab326-B13","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1128\/AAC.04729-14","article-title":"Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A","volume":"59","author":"Parry","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021111722581030300_dkab326-B14","doi-asserted-by":"crossref","first-page":"e0007955","DOI":"10.1371\/journal.pntd.0007955","article-title":"Treatment responses to azithromycin and ciprofloxacin in uncomplicated Salmonella Typhi infection: a comparison of clinical and microbiological data from a controlled human infection model","volume":"13","author":"Jin","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2021111722581030300_dkab326-B15","year":"2019"},{"key":"2021111722581030300_dkab326-B16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1128\/CMR.00116-14","article-title":"The role of epidemic resistance plasmids and international high- risk clones in the spread of multidrug-resistant Enterobacteriaceae","volume":"28","author":"Mathers","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"2021111722581030300_dkab326-B17","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1038\/s41467-019-11756-y","article-title":"OmpK36-mediated carbapenem resistance attenuates ST258 Klebsiella pneumoniae in vivo","volume":"10","author":"Wong","year":"2019","journal-title":"Nat Commun"},{"key":"2021111722581030300_dkab326-B18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/MCC.0000000000000235","article-title":"New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections","volume":"21","author":"Bassetti","year":"2015","journal-title":"Curr Opin Crit Care"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/76\/12\/3197\/41136423\/dkab326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/76\/12\/3197\/41136423\/dkab326.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T15:15:38Z","timestamp":1673104538000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/12\/3197\/6371920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,9,17]]},"published-print":{"date-parts":[[2021,11,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab326","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,9,17]]}}}